Combination of ERK2 Inhibitor VX-11e and Voreloxin Synergistically Enhances Anti-proliferative and Pro-apoptotic Effects in Leukemia Cells

Overview

Journal Apoptosis

Publisher Springer

Date 2019 Sep 5

PMID 31482470

Citations 7

Authors

Ewa Jasek-Gajda

Halina Jurkowska

Malgorzata Jasinska

Jan A Litwin

Grzegorz J Lis

Affiliations

Soon will be listed here.

Abstract

ERK1/2 inhibitors are new promising anticancer drugs. The aim of this study was to investigate the effect of the combination of ERK2 inhibitor VX-11e and voreloxin on MOLM-14, K562, REH and MOLT-4 leukemia cell lines. We found that VX-11e alone and in combination with voreloxin significantly decreased ERK activation in all cell lines tested. To evaluate the interactions of the drugs, cells were treated for 24 h with VX-11e or voreloxin alone and in combination at fixed ratios based on IC values. The combinatorial effects of both drugs were synergistic over a wide range of concentrations in MOLM-14, REH and MOLT-4 cell lines. In K562 cells, three effects were found to be additive, one antagonistic and only one synergistic. The results showed that incubation with both VX-11e and voreloxin inhibited the growth of leukemia cells, affected cell cycle and induced apoptosis. Furthermore, the molecular mechanism of these effects might be attributed to an increased expression of p21 and a decreased expression of survivin and NF-κB in all cell lines tested except from K562 cells. In conclusion, combination of VX-11e and voreloxin can exert a synergistic anticancer effect in leukemia cells.

Citing Articles

Enhanced conversion of T cells into CAR T cells by modulation of the MAPK/ERK pathway.

Adabi E, Charitidis F, Thalheimer F, Guaza-Lasheras M, Clarke C, Buchholz C Cell Rep Med. 2025; 6(2):101970.

PMID: 39938523 PMC: 11866553. DOI: 10.1016/j.xcrm.2025.101970.

Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma.

Wu Y, Li F, Yang C, Zhang X, Xue Z, Sun Y Sci Rep. 2025; 15(1):954.

PMID: 39762261 PMC: 11704019. DOI: 10.1038/s41598-024-82109-z.

Synergism of d-limonene and temozolomide on migratory and apoptotic behaviors of human glioblastoma cell lines.

Gautam M, Gabrani R Bioimpacts. 2024; 14(5):27681.

PMID: 39296804 PMC: 11406426. DOI: 10.34172/bi.2023.27681.

ERK2-topoisomerase II regulatory axis is important for gene activation in immediate early genes.

Bunch H, Kim D, Naganuma M, Nakagawa R, Cong A, Jeong J Nat Commun. 2023; 14(1):8341.

PMID: 38097570 PMC: 10721843. DOI: 10.1038/s41467-023-44089-y.

The molecular biology and therapeutic potential of Nrf2 in leukemia.

Khodakarami A, Adibfar S, Karpisheh V, Abolhasani S, Jalali P, Mohammadi H Cancer Cell Int. 2022; 22(1):241.

PMID: 35906617 PMC: 9336077. DOI: 10.1186/s12935-022-02660-5.

References

Sheikh M, ROCHEFORT H, Garcia M . Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene. 1995; 11(9):1899-905. View

Shin M, Franks C, Hsu K . Isoform-selective activity-based profiling of ERK signaling. Chem Sci. 2018; 9(9):2419-2431. PMC: 5909473. DOI: 10.1039/c8sc00043c. View

Mobaraki R, Karimi M, Alikarami F, Farhadi E, Amini A, Bashash D . RITA induces apoptosis in p53-null K562 leukemia cells by inhibiting STAT5, Akt, and NF-κB signaling pathways. Anticancer Drugs. 2018; 29(9):847-853. DOI: 10.1097/CAD.0000000000000651. View

Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y . MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation. Oncogene. 2003; 22(49):7774-80. DOI: 10.1038/sj.onc.1206901. View

Nishioka C, Ikezoe T, Yang J, Yokoyama A . Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. Apoptosis. 2010; 15(7):795-804. DOI: 10.1007/s10495-010-0483-y. View

Takizawa B, Uchio E, Cohen J, Wheeler M, Weiss R . Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. Cancer Invest. 2007; 25(8):678-84. DOI: 10.1080/07357900701600954. View

Li D, Hu C, Li H . Survivin as a novel target protein for reducing the proliferation of cancer cells. Biomed Rep. 2018; 8(5):399-406. PMC: 5920485. DOI: 10.3892/br.2018.1077. View

Jasek-Gajda E, Gajda M, Jasinska M, Litwin J, Lis G . TAK-733, a Selective MEK Inhibitor, Enhances Voreloxin-induced Apoptosis in Myeloid Leukemia Cells. Anticancer Res. 2018; 38(11):6147-6156. DOI: 10.21873/anticanres.12967. View

He L, Tang J, Andersson E, Timonen S, Koschmieder S, Wennerberg K . Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. Cancer Res. 2018; 78(9):2407-2418. DOI: 10.1158/0008-5472.CAN-17-3644. View

10.

Chang B, Watanabe K, Broude E, Fang J, Poole J, Kalinichenko T . Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A. 2000; 97(8):4291-6. PMC: 18232. DOI: 10.1073/pnas.97.8.4291. View

11.

Jain N, Curran E, Iyengar N, Diaz-Flores E, Kunnavakkam R, Popplewell L . Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2013; 20(2):490-8. PMC: 4310865. DOI: 10.1158/1078-0432.CCR-13-1311. View

12.

Zhang W, Ruvolo V, Gao C, Zhou L, Bornmann W, Tsao T . Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Mol Cancer Ther. 2014; 13(7):1848-59. PMC: 4090272. DOI: 10.1158/1535-7163.MCT-13-0576. View

13.

Carter B, Milella M, Altieri D, Andreeff M . Cytokine-regulated expression of survivin in myeloid leukemia. Blood. 2001; 97(9):2784-90. DOI: 10.1182/blood.v97.9.2784. View

14.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y . Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2008; 64(1):53-65. DOI: 10.1007/s00280-008-0850-3. View

15.

Yap J, Worlikar S, MacKerell Jr A, Shapiro P, Fletcher S . Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics. ChemMedChem. 2010; 6(1):38-48. PMC: 3477473. DOI: 10.1002/cmdc.201000354. View

16.

Lunghi P, Tabilio A, DallAglio P, Ridolo E, Carlo-Stella C, Pelicci P . Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. 2003; 17(9):1783-93. DOI: 10.1038/sj.leu.2403032. View

17.

Bhatia U, Danishefsky K, Traganos F, Darzynkiewicz Z . Induction of apoptosis and cell cycle-specific change in expression of p53 in normal lymphocytes and MOLT-4 leukemic cells by nitrogen mustard. Clin Cancer Res. 1995; 1(8):873-80. View

18.

Carra G, Torti D, Crivellaro S, Panuzzo C, Taulli R, Cilloni D . The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias. Oncotarget. 2016; 7(40):66287-66298. PMC: 5323234. DOI: 10.18632/oncotarget.11507. View

19.

Sherr C, Roberts J . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13(12):1501-12. DOI: 10.1101/gad.13.12.1501. View

20.

LeFloch R, Pouyssegur J, Lenormand P . Total ERK1/2 activity regulates cell proliferation. Cell Cycle. 2009; 8(5):705-11. DOI: 10.4161/cc.8.5.7734. View